<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291654</url>
  </required_header>
  <id_info>
    <org_study_id>SZMC-Hammerman-Acamol-2011</org_study_id>
    <nct_id>NCT01291654</nct_id>
  </id_info>
  <brief_title>Paracetamol and Patent Ductus Arteriosus (PDA)</brief_title>
  <official_title>Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that paracetamol will be similarly effective to ibuprofen in
      treating PDA in the premature neonate, with fewer side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm neonates with a hemodynamically significant PDA will potentially be candidates for
      study. After obtaining parental consent, the infants will be prospectively and randomly
      assigned to one of two groups: 1.po Paracetamol at a dose of 15 mg/kg every 6 hours at x 3
      days or Group 2- IV indomethacin - 0.2 mg/kg/dose q 12h for three doses; or IV Ibuprofen 10
      mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
      (total of 3 doses).Clinical staff will be blinded as to the study group assignment of the
      babies and since the group 1 drug is to be given every six hours, all babies will receive a
      parenteral substance every 6 hours. For Group 2 infants, the intermittent doses will be IV
      D5W alternating with drug.All infants will fed trophic feeds (20 cc/kg/day) during the
      treatment for ductal closure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Closure of the Ductus</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of peripheral vasoconstriction</measure>
    <time_frame>48 hours</time_frame>
    <description>Doppler flow velocity in anterior cerebral artery, superior mesenteric artery and renal artery will be measured before and after pharmacologic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of hepatotoxicity</measure>
    <time_frame>1 week</time_frame>
    <description>Liver function will be compared between the two study groups at 1 week following completion of pharmacologic treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>po Paracetamol 15 mg/kg every 6 hours x 3 days</description>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NSAID</intervention_name>
    <description>IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).</description>
    <arm_group_label>NSAID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D5W</intervention_name>
    <description>Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.</description>
    <arm_group_label>NSAID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Echocardiographic diagnosis of hemodynamically significant patent ductus arteriosus

        Exclusion Criteria:

          -  Major congenital anomalies

          -  Life-threatening infection

          -  Active NEC and/or intestinal perforation

          -  Recent (within the previous 24 hours) intraventricular hemorrhage Grade 3-4

          -  Urine output &lt;1 ml per kilogram per hour during the preceding 8 hours

          -  Serum creatinine concentration of &gt;1.6 mg %

          -  Platelet count of &lt;60,000 per cc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Hammerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Hammerman, MD</last_name>
    <phone>+9722666-6238</phone>
    <email>cathy@cc.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Bin-Nun, MD</last_name>
    <phone>+9722666-6757</phone>
    <email>alona.binnun@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Hammerman, MD</last_name>
      <phone>+9722666-6238</phone>
      <email>cathy@cc.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Cathy Hammerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Cathy Hammerman</investigator_full_name>
    <investigator_title>Prof. Pediatrics</investigator_title>
  </responsible_party>
  <keyword>PDA</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Ibuprofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

